In Vitro Fertilization Market Size to Surpass USD 42.95 BN by 2032
The global in vitro fertilization market size was estimated at USD 24.6 billion in 2022 and is expected to surpass around USD 42.95 billion by 2032 and poised to grow at a compound annual growth rate (CAGR) of 5.73% during the forecast period 2023 to 2032.
Key Takeaways:
In Vitro Fertilization Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 26.01 Billion |
| Market Size by 2032 | USD 42.95 Billion |
| Growth Rate From 2023 to 2032 | CAGR of 5.73% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Instrument, Procedure type, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Bayer AG, Boston IVF; Cook Medical LLC; EMD Serono, Inc.; Ferring B.V.; FUJIFILM Irvine Scientific (FUJIFILM Holdings Corp.); Genea Biomedx; Merck & Co., Inc.; OvaScience, Inc.; Progyny, Inc.; The Cooper Companies, Inc.; Thermo Fisher Scientific, Inc.; Vitrolife |
The market's growth can be attributed to the continuous efforts of the market players, an increase in the incidence of infertility due to lifestyle changes, and government initiatives to improve reimbursement policies. The expansion of fertility procedures, such as ICSI for treating infertility, is expected to have a positive impact on market growth.
Moreover, the availability of genomic testing facilities that enable the prevention of the transfer of genetic disorders during in vitro fertilization (IVF) is expected to drive the IVF market. The insurance providers are providing coverage for IVF procedures owing to an increase in the number of IVF treatments. For instance, in May 2023, Pacific Blue Cross introduced an enhanced Personal Health Insurance, a health & dental plan, which incorporates family planning benefits, including coverage for fertility drugs, fertility treatments, and adoption. With this enhancement, Pacific Blue Cross became the first and only provider in Canada to offer family planning benefits as part of an individual health & dental plan. This led to competitive pricing and moderated the IVF treatment costs. The procedure has been a successfully practiced technology, driving the market with more treatment automation and standardization.
A decline in the Total Fertility Rate (TFR) results from factors, such as a behavioral shift in society. These factors include a shift from rural to urban societies, increased age of the first pregnancy, postponement of marriage, increased employment, and lower marriage rates. In March 2020, in-person fertility treatments in the U.S. and Canada were suspended due to COVID-19 by the American Society of Reproductive Medicine and Canadian Fertility and Andrology Society. However, treatment is resuming in many countries with the ease of COVID-19 restrictions. The research findings published by the Obstetrics & Gynecology journal in January 2022 reported that COVID-19 vaccines wouldn't harm IVF outcomes. This is expected to prove significant in promoting the uptake of IVF in eligible vaccinated individuals.
Procedure Type Insights
Based on type, the market is categorized into frozen non-donor, fresh non-donor, fresh donor, and frozen donor. The frozen non-donor segment dominated the market with the largest revenue share of 43.2% in 2022 and is expected to witness the fastest growth over the forecast period. Certain factors contributing to the high share are the cost-effectiveness as compared to fresh nondonor and the less invasive nature of the procedure. The fresh donor segment is expected to grow significantly over the forecast period. As per the 2020 National ART Summary report, around 1,477 ART cycles were performed using fresh donors, with around 53.9% of transfers resulting in live-birth deliveries in the U.S.
Although some centers offer risk-sharing plans and refunds only for three cycles, the Advanced Fertility Center of Chicago has designed the IVF reimbursement plan to provide a 100% refund for up to four cycles with fresh embryos. The Human Fertilization and Embryology Act 1990 does not cover fresh sperm donation, and hence, there is rising concern about sperm donors not being screened before donation. The HEFA does not guarantee sperm donation services, which are unlicensed. Hence, HEFA has revised its guidelines, wherein fresh sperm must be quarantined for 180 days for HIV screening. NHS funds a smaller proportion of fertility treatment using donated gametes to homosexuals and single parents.
End-use Insights
The fertility clinics segment dominated the market with the largest revenue share of 80.8% in 2022 and is expected to witness the fastest growth over the forecast period. This can be attributed to a rise in demand for ART treatments; the number of fertility clinics and ART centers is increasing considerably. Factors, such as cost-effectiveness, availability of specialists, and minimal or no chances of Hospital-Acquired Infections (HAIs), are anticipated to drive the growth of the fertility clinics segment. IVF treatments are also performed in hospitals.
The hospitals and other settings segments is expected to grow at a significant CAGR over the forecast period. Numerous multispecialty hospitals provide infertility treatments, including In Vitro Fertilization (IVF). The growing accessibility and availability of these treatments have contributed to a greater inclination toward hospitals for infertility care. However, hospital IVF treatments cost more than fertility clinics. This is partly due to the need for highly skilled physicians and staff to perform these intricate procedures. Consequently, having a dedicated IVF staff in hospitals is considered a less favored approach due to the expenses related to their employment, remuneration, and training. These costs can be particularly high in developed countries like the U.S. and the UK.
Instrument Insights
Based on instruments, the market is further segmented into culture media, capital equipment, and IVF disposable devices. The culture media segment dominated the market with the largest revenue share of 41.1% in 2022. This can be attributed to factors, such as the availability of funding and an increase in research activities to improve the culture media. In July 2022, FUJIFILM Irvine Scientific launched a mineral oil for embryo culture, Heavy Oil for Embryo Culture. It is a sterile mineral oil that addresses major concerns in IVF procedures, including pH, osmolality changes, and media preservation, owing to its ideal weight viscosity.
The disposable devices segment is expected to grow at the fastest CAGR during the forecast years. The growth of this segment is owing to the industry players introducing disposable devices, such as needles, slides, and chambers, to meet sterility and regulatory requirements. Such developments are expected to increase the adoption of disposable IVF devices. Disposable slides for sperm counting, an imaging-based tracking system to isolate the best motile sperm, and the use of disposable microchips are some of the innovations witnessed by the market in recent years.
Regional Insights
Europe dominated the market with the largest revenue share of 38% in 2022. This can be attributed to factors, such as a noticeable surge in medical tourism, with an increasing number of Americans choosing to travel to the Czech Republic for more cost-effective IVF treatments. Moreover, individuals who cannot afford to travel abroad are now seeking IVF treatments within the United States at around one-third of the cost charged by clinics in the country. In July 2022, Fairtility obtained approval from the European Union to use AI for embryo assessment. The EU's new medical device regulation standards have enabled the development of a commercially available AI tool, which holds the potential to boost the success rate of IVF procedures.
These regulations pave the way for advanced AI technologies to be introduced in the market, providing fertility clinics and healthcare professionals with innovative tools to enhance IVF outcomes. The AI tool's focus includes aiding in embryo selection, grading, and predicting the optimal embryo implantation. Asia Pacific is expected to witness the fastest growth over the forecast period. This can be attributed to a surge in the demand for IVF treatment due to several factors. Fertility tourism, foreign investment targeting economically developing countries, and evolving regulatory conditions contribute to this growth.
In addition, lifestyle changes, including increased obesity, stress, lack of exercise, improper eating habits, insufficient nutrition, rise in pollution, and the prevalence of medical conditions like diabetes, have led to a higher incidence of infertility in the region. North America is also expected to witness increasing demand for fertility treatment in the coming years. Standardization of procedures through automation, regulatory reforms, government funding for egg/sperm storage, and the introduction of more IVF treatments by industry players are among the major factors contributing to the growth of the regional market.
Some of the prominent players in the In Vitro Fertilization Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global In Vitro Fertilization market.
By Instrument
By Procedure Type
By End-use
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.1.1. Procedure Type
1.1.2. End-Use
1.1.3. Instrument
1.1.4. Region
1.2. Estimates and Forecast Timeline
1.3. Research Methodology
1.3.1. Information procurement
1.3.2. Purchased Database
1.3.3. Nova one advisors Internal Database
1.3.4. Secondary Sources
1.3.5. Primary Research
1.3.6. Details of Primary Research
1.4. Information or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.5.1. Volume Price Analysis
1.6. List of Secondary Sources
1.7. List of Abbreviations
1.8. Research Objectives
1.8.1. Objective - 1
1.8.2. Objective - 2
1.8.3. Objective - 3
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.2.1. Procedure Type
2.2.2. End-Use
2.2.3. Instrument
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.2. Market Segmentation
3.3. Penetration & Growth Prospect Mapping
3.4. Clinical Trials
3.5. User Perspective Analysis
3.5.1. Consumer Behavior Analysis
3.5.2. Market Influencer Analysis
3.6. Market Dynamics
3.6.1. Market Driver Analysis
3.6.2. Market Restraint Analysis
3.7. Industry Analysis Tools
3.7.1. Porter's Five Forces Analysis
3.7.2. PESTLE Analysis
3.7.3. Qualitative Analysis: Impact of COVID-19 on IVF Market
Chapter 4. In Vitro Fertilization Market: Procedure Type Analysis
4.1. In Vitro Fertilization by Procedure Type Market Share Analysis, 2023 - 2032
4.2. Segment Dashboard
4.3. Global In Vitro Fertilization Procedures Market, by Type, 2020 - 2032
4.4. Market Size and Forecasts and Trend Analysis, 2020 - 2032 for the Procedure Type
4.4.1. Fresh Nondonor
4.4.1.1. Fresh nondonor market, 2020 - 2032
4.4.2. Frozen Nondonor
4.4.2.1. Frozen nondonor market, 2020 - 2032
4.4.3. Fresh Donor
4.4.3.1. Fresh donor market, 2020 - 2032
4.4.4. Frozen Donor
4.4.4.1. Frozen donor market, 2020 - 2032
Chapter 5. In Vitro Fertilization Market: End-use Analysis
5.1. In Vitro Fertilization End-use Market Share Analysis, 2023 - 2032
5.2. Segment Dashboard
5.3. Market Size and Forecasts and Trend Analysis, 2020 - 2032 for the following End-Use
5.3.1. Fertility Clinics
5.3.1.1. Fertility clinics market, 2020 - 2032
5.3.2. Hospitals & Other Settings
5.3.2.1. Hospitals & other settings market, 2020 - 2032
Chapter 6. In Vitro Fertilization Market: Instrument Analysis
6.1. In Vitro Fertilization (IVF) Market Share Analysis, 2023 - 2032
6.2. Segment Dashboard
6.3. Global IVF Market, by Instrument, 2022 to 2030
6.4. Market Size & Forecasts and Trend Analysis, 2018 to 2030 for the Instrument
6.4.1. Culture Media
6.4.1.1. Culture media market, 2020 - 2032
6.4.2. Disposable Devices
6.4.2.1. Disposable devices market, 2020 - 2032
6.4.3. Capital Equipment
6.4.3.1. Capital equipment market, 2020 - 2032
Chapter 7. Regional Outlook
7.1. IVF Market by Region: Key Marketplace Takeaway
7.2. List of Few Fertility Clinics
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. MEA
7.3. North America
7.3.1. North America IVF market, 2020 - 2032
7.3.2. U.S.
7.3.2.1. U.S. estimated fertility rate, 2020 - 2032
7.3.2.2. Regulatory framework
7.3.2.3. Reimbursement scenario
7.3.2.4. U.S. IVF market, 2020 - 2032
7.3.3. Canada
7.3.3.1. Canada estimated fertility rate, 2020 - 2032
7.3.3.2. Regulatory framework
7.3.3.3. Reimbursement scenario
7.3.3.4. Canada IVF market, 2020 - 2032
7.4. Europe
7.4.1. Europe IVF market, 2020 - 2032
7.4.2. France
7.4.2.1. France estimated fertility rate, 2020 - 2032
7.4.2.2. Regulatory framework
7.4.2.3. Reimbursement scenario
7.4.2.4. France IVF market, 2020 - 2032
7.4.3. Germany
7.4.3.1. Germany estimated fertility rate, 2020 - 2032
7.4.3.2. Regulatory framework
7.4.3.3. Reimbursement Scenario
7.4.3.4. Germany IVF market, 2020 - 2032
7.4.4. Italy
7.4.4.1. Italy estimated fertility rate, 2020 - 2032
7.4.4.2. Regulatory framework
7.4.4.3. Reimbursement scenario
7.4.4.4. Italy IVF market, 2020 - 2032
7.4.5. Spain
7.4.5.1. Spain estimated fertility rate, 2020 - 2032
7.4.5.2. Regulatory framework
7.4.5.3. Reimbursement scenario
7.4.5.4. Spain IVF market, 2020 - 2032
7.4.6. UK
7.4.6.1. UK estimated fertility rate, 2020 - 2032
7.4.6.2. Regulatory framework
7.4.6.3. Reimbursement scenario
7.4.6.4. UK IVF market, 2020 - 2032
7.4.7. Belgium
7.4.7.1. Belgium estimated fertility rate, 2020 - 2032
7.4.7.2. Regulatory framework
7.4.7.3. Reimbursement scenario
7.4.7.4. Belgium IVF market, 2020 - 2032
7.4.8. The Netherlands
7.4.8.1. The Netherlands estimated fertility rate, 2020 - 2032
7.4.8.2. Regulatory framework
7.4.8.3. Reimbursement scenario
7.4.8.4. The Netherlands IVF market, 2020 - 2032
7.4.9. Switzerland
7.4.9.1. Switzerland estimated fertility rate, 2020 - 2032
7.4.9.2. Regulatory framework
7.4.9.3. Reimbursement scenario
7.4.9.4. Switzerland IVF market, 2020 - 2032
7.5. Asia Pacific
7.5.1. Asia Pacific IVF market, 2020 - 2032
7.5.2. Japan
7.5.2.1. Japan estimated fertility rate, 2020 - 2032
7.5.2.2. Regulatory framework
7.5.2.3. Reimbursement scenario
7.5.2.4. Japan IVF market, 2020 - 2032
7.5.3. China
7.5.3.1. China estimated fertility rate, 2020 - 2032
7.5.3.2. Regulatory framework
7.5.3.3. Reimbursement scenario
7.5.3.4. China IVF market, 2020 - 2032
7.5.4. India
7.5.4.1. India estimated fertility rate, 2020 - 2032
7.5.4.2. Regulatory framework
7.5.4.3. Reimbursement scenario
7.5.4.4. India IVF market, 2020 - 2032
7.5.5. Australia
7.5.5.1. Australia estimated fertility rate, 2020 - 2032
7.5.5.2. Regulatory framework
7.5.5.3. Reimbursement scenario
7.5.5.4. Australia IVF market, 2020 - 2032
7.5.6. South Korea
7.5.6.1. South Korea estimated fertility rate, 2020 - 2032
7.5.6.2. Regulatory framework
7.5.6.3. Reimbursement scenario
7.5.6.4. South Korea IVF market, 2020 - 2032
7.6. Latin America
7.6.1. Latin America IVF market, 2020 - 2032
7.6.2. Brazil
7.6.2.1. Brazil estimated fertility rate, 2020 - 2032
7.6.2.2. Regulatory framework
7.6.2.3. Reimbursement scenario
7.6.2.4. Brazil IVF market, 2020 - 2032
7.6.3. Mexico
7.6.3.1. Mexico estimated fertility rate, 2020 - 2032
7.6.3.2. Regulatory framework
7.6.3.3. Reimbursement scenario
7.6.3.4. Mexico IVF market, 2020 - 2032
7.6.4. Argentina
7.6.4.1. Argentina estimated fertility rate, 2020 - 2032
7.6.4.2. Regulatory framework
7.6.4.3. Reimbursement scenario
7.6.4.4. Argentina IVF market, 2020 - 2032
7.7. Middle East & Africa
7.7.1. MEA IVF market, 2020 - 2032
7.7.2. South Africa
7.7.2.1. South Africa estimated fertility rate, 2020 - 2032
7.7.2.2. Regulatory framework
7.7.2.3. Reimbursement scenario
7.7.2.4. South Africa IVF market, 2020 - 2032
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia estimated fertility rate, 2020 - 2032
7.7.3.2. Regulatory framework
7.7.3.3. Reimbursement scenario
7.7.3.4. Saudi Arabia IVF market, 2020 - 2032
7.7.4. UAE
7.7.4.1. UAE estimated fertility rate, 2020 - 2032
7.7.4.2. Regulatory framework
7.7.4.3. Reimbursement scenario
7.7.4.4. UAE IVF market, 2020 - 2032
Chapter 8. Competitive Analysis
8.1. Company Profiles
8.1.1. OvaScience, Inc.
8.1.1.1. Overview
8.1.1.2. Financial Performance
8.1.1.3. Service Benchmarking
8.1.1.4. Strategic Initiatives
8.1.2. Vitrolife AB (publ)
8.1.2.1. Overview
8.1.2.2. Financial Performance
8.1.2.3. Service Benchmarking
8.1.2.4. Strategic Initiatives
8.1.3. Emd Serono, Inc.
8.1.3.1. Overview
8.1.3.2. Financial Performance
8.1.3.3. Service Benchmarking
8.1.3.4. Strategic Initiatives
8.1.4. FUJIFILM Irvine Scientific
8.1.4.1. Overview
8.1.4.2. Financial Performance
8.1.4.3. Service Benchmarking
8.1.4.4. Strategic Initiatives
8.1.5. The Cooper Companies, Inc.
8.1.5.1. Overview
8.1.5.2. Financial Performance
8.1.5.3. Service Benchmarking
8.1.5.4. Strategic Initiatives
8.1.6. Thermo Fisher Scientific, Inc.
8.1.6.1. Overview
8.1.6.2. Financial Performance
8.1.6.3. Service Benchmarking
8.1.6.4. Strategic Initiatives
8.1.7. Bayer AG
8.1.7.1. Overview
8.1.7.2. Financial Performance
8.1.7.3. Service Benchmarking
8.1.7.4. Strategic Initiatives
8.1.8. Merck & Co., Inc.
8.1.8.1. Overview
8.1.8.2. Financial Performance
8.1.8.3. Service Benchmarking
8.1.8.4. Strategic Initiatives
8.1.9. Cook Medical LLC (Cook Group)
8.1.9.1. Overview
8.1.9.2. Financial Performance
8.1.9.3. Service Benchmarking
8.1.9.4. Strategic Initiatives
8.1.10. Genea Biomedx
8.1.10.1. Overview
8.1.10.2. Financial Performance
8.1.10.3. Service Benchmarking
8.1.10.4. Strategic Initiatives
8.1.11. Progyny, Inc.
8.1.11.1. Overview
8.1.11.2. Financial Performance
8.1.11.3. Service Benchmarking
8.1.11.4. Strategic Initiatives
8.1.12. Boston IVF
8.1.12.1. Overview
8.1.12.2. Financial Performance
8.1.12.3. Service Benchmarking
8.1.12.4. Strategic Initiatives
8.1.13. Ferring Pharmaceutical B.V.
8.1.13.1. Overview
8.1.13.2. Financial Performance
8.1.13.3. Service Benchmarking
8.1.13.4. Strategic Initiatives
8.2. Company Categorization
8.3. Company Market Position Analysis
8.4. Strategy Mapping
Chapter 9. Recommendations/Key Market Insights
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers